advanced myelodysplastic syndrome
Conditions
Interventions
None listed
Sponsors
Kanto Study Group for Cell Therapy
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients with de novo or therapy-related MDS according to WHO classification. 2.MDS patients with Intermediate-2 or High in IPSS and/or Intermediate, High or Very High in IPSS-R. 3.Patients who are planned to receive allogeneic transplantation within 90 days from the registration of this study. 4.Patients who can participate in this study immediately after the decision for HSCT. 5.Patients who are more than 15 years old.
Exclusion criteria
Exclusion criteria: 1. Patients who have 20% or more than 20% of blast in BM or PB. 2. Patients who have had received azacitidine or AML-type chemotherapy for MDS. 3. Patients who have received allogeneic transplantation. 4. Patients who do not provide written informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3-year overall survival after the registration | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)the rate of patients who actually receive HSCT within 90 days from the registration 2)3-year overall survival after HSCT 3)3-year progression-free survival after HSCT 4)non-relapse mortality after HSCT, relapse rate after HSCT | — |
Countries
Japan
Contacts
Public ContactShinichi Kako
Jichi Medical University Saitama Medical Center Division of Hematology
Outcome results
None listed